TY - JOUR
T1 - Further evidence for the depressive effects of cytokines
T2 - Anhedonia and neurochemical changes
AU - Anisman, Hymie
AU - Kokkinidis, Larry
AU - Merali, Zul
N1 - Funding Information:
Supported by Grants from the Canadian Institute of Health Research. We are indebted to Shawn Hayley for his comments. H. Anisman holds a Canada Research Chair in Neurosciences, and is an Ontario Mental Health Senior Research Fellow.
PY - 2002
Y1 - 2002
N2 - Although human studies have emphasized a role for IL-2 in depressive illness, limited attention has been devoted to the behavioral and neurochemical effects of this cytokine in animal studies. The present review assesses the behavioral effects of IL-2 in rodents, in counterpoint to the effects of interleukin-1β (IL-1β), necrosis factor-α (TNF-α) and endotoxin challenge. Unlike IL-1β, systemic IL-2 provokes modest effects on hypothalamic-pituitary-adrenal (HPA) functioning, and does not provoke marked signs of illness or anxiety. In some respects, however, IL-2 elicits effects reminiscent of traditional stressors, including anhedonia (diminished pleasure gained from otherwise rewarding stimuli). Additionally, when chronically administered, IL-2 may impact on cognitive processes, including spatial working memory. While IL-2 may induce depressive-like symptoms, the available data are sparse, have hardly considered the impact of chronic cytokine treatment, only assessed behavior in a narrow range of tests, and it remains to be established whether the effects of IL-2 are modifiable by antidepressant treatments. Finally, as the effects of IL-2 on CNS processes vary in a biphasic fashion, and may also engender neurotoxic effects, further analyses are necessary to discern under what conditions this cytokine provokes depressive-like behavioral outcomes.
AB - Although human studies have emphasized a role for IL-2 in depressive illness, limited attention has been devoted to the behavioral and neurochemical effects of this cytokine in animal studies. The present review assesses the behavioral effects of IL-2 in rodents, in counterpoint to the effects of interleukin-1β (IL-1β), necrosis factor-α (TNF-α) and endotoxin challenge. Unlike IL-1β, systemic IL-2 provokes modest effects on hypothalamic-pituitary-adrenal (HPA) functioning, and does not provoke marked signs of illness or anxiety. In some respects, however, IL-2 elicits effects reminiscent of traditional stressors, including anhedonia (diminished pleasure gained from otherwise rewarding stimuli). Additionally, when chronically administered, IL-2 may impact on cognitive processes, including spatial working memory. While IL-2 may induce depressive-like symptoms, the available data are sparse, have hardly considered the impact of chronic cytokine treatment, only assessed behavior in a narrow range of tests, and it remains to be established whether the effects of IL-2 are modifiable by antidepressant treatments. Finally, as the effects of IL-2 on CNS processes vary in a biphasic fashion, and may also engender neurotoxic effects, further analyses are necessary to discern under what conditions this cytokine provokes depressive-like behavioral outcomes.
KW - Anxiety
KW - Depression
KW - Dopamine
KW - Interleukin-1
KW - Interleukin-2
KW - Lipopolysaccharide
KW - Norepinephrine
KW - Serotonin
UR - http://www.scopus.com/inward/record.url?scp=0036428988&partnerID=8YFLogxK
U2 - 10.1016/S0889-1591(02)00011-9
DO - 10.1016/S0889-1591(02)00011-9
M3 - Article
C2 - 12401468
AN - SCOPUS:0036428988
SN - 0889-1591
VL - 16
SP - 544
EP - 556
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
IS - 5
ER -